Europe open: Stocks reverse early losses, healthcare leads
20th Jul 2020 07:56
(Sharecast News) - Stocks have recovered from early selling following news that European Union leaders meeting in Brussels had made progress on the terms for a reconstruction fund.
Read moreSynairgen treatment reduces risk of 'severe' Covid-19 by 79%
20th Jul 2020 07:20
(Sharecast News) - Synairgen's Covid-19 treatment sharply reduced the risk of patients developing severe forms of the illness provoked by the novel coronavirus, clinical trials showed.
Read moreSynairgen expands Covid-19 trial nationwide
18th Jun 2020 09:12
(Sharecast News) - Synairgen is to expand trials of a potential treatment for Covid-19 nationally, the respiratory drug specialist said on Thursday.
Read moreSunday share tips: Synairgen, Hollywood Bowl
29th Mar 2020 21:00
(Sharecast News) - The Sunday Times's Sabah Meddings recommends buying shares of Synairgen arguing that the Covid-19 pandemic may have given the firm a new lease on life.
Read moreSunday newspaper round-up: Restrictions, Unemployment, Blood plasma
29th Mar 2020 20:57
(Sharecast News) - "Life in Britain will not return to normal for six months, England's deputy chief medical officer has warned, as ministers begin preparing the public for an extended period of lockdown. At the government's daily press conference, Jenny Harries said that strict social distancing rules may have to be in place for between two and three months. But she added that it would be a further three months before all restrictions were lifted, and even then there were likely to be "bumps" as new clusters of cases of coronavirus were identified." - Sunday Times
Read moreSynairgen to begin trial of potential Covid-19 therapy
18th Mar 2020 11:17
(Sharecast News) - Respiratory drug discovery company Synairgen has received expedited approvals from the Medicines and Healthcare Products Regulatory Agency (MHRA) and Health Research Authority (HRA) to conduct a trial of 'SNG001', an inhaled formulation of interferon-beta-1a, in Covid-19 coronavirus patients, to potentially assist with the global virus pandemic.
Read moreSynairgen broadens SNG001 trial after committee review
14th Mar 2019 14:47
(Sharecast News) - Respiratory drug discovery and development company Synairgen announced on Thursday that its data safety monitoring committee had completed its planned safety review of the second part of the phase 2 clinical trial of its inhaled interferon-beta (IFN-beta) therapeutic candidate, SNG001, in patients with chronic obstructive pulmonary disease (COPD).
Read moreSynairgen begins second part of SNG001 Phase II trial
22nd Oct 2018 09:20
(Sharecast News) - Respiratory drug discovery and development company Synairgen has started the second part of its Phase II clinical trial for its wholly-owned inhaled interferon-beta (IFN-beta) therapeutic candidate, SNG001, in patients with chronic obstructive pulmonary disease (COPD), it announced on Monday.
Read moreSynairgen shares drop as AstraZeneca stops asthma drug study
12th Oct 2016 09:52
(ShareCast News) - Synairgen's, the respiratory drug discovery and development company, hit the skids after its partner Astrazeneca announced that it has dropped its clinical trial for asthma drug AZD9412. AZD9412, which is a form of inhaled interferon beta, was investigated in an INEXAS trial in pa
Read moreSynairgen's profit dips, R and D expenditure reduced
16th Sep 2015 13:03
(ShareCast News) - Synairgen has posted an after tax loss of £0.91m for the six months to 30 June, down from a profit of £1.90m in the same period last year. The respiratory drug discovery and development company announced its unaudited interim results for the six months ended 30 June 2015. Researc
Read moreSynairgen shares surge on research collaboration deal
5th Aug 2015 10:21
(ShareCast News) - Synairgen surged after announcing that it has entered into a research collaboration deal with Australian pharmaceutical company Pharmaxis. The respiratory drug discovery and development company said they will develop a selective inhibitor to the lysyl oxidase type 2 enzyme to trea
Read moreAstraZeneca starts next phase of testing on Synairgen asthma drug
22nd Jul 2015 10:44
(ShareCast News) - Synairgen announced AstraZeneca started another phase of testing on its asthma drug. AIM listed Synairgen said AstraZeneca begun its Phase IIa trial of the drug AZD9412 and expected results in early 2017. AstraZeneca would test 220 asthma patients whose conditions were exacerbate
Read moreTuesday broker round-up UPDATE
21st Oct 2014 08:50
African Barrick Gold: JP Morgan cuts target price from 340p to 300p and stays with its overweight rating. Anglo American: JP Morgan raises target price from 1240p to 1310p, while leaving its underweight rating unchanged. Investec increases target price from 1573p to 1603p and stays with its buy reco
Read moreSynairgen raises funds to develop AstraZeneca drug
4th Jul 2014 12:11
Synairgen has placed 12.2m shares to raise funds for the assessment and preparation of SNG001, the drug recently licensed from AstraZeneca, across five projects that it has identified as the most suitable direction for its development. The drugs company raised around £5.3m before expenses after is
Read moreSunday share tips: Whitbread, Petra Diamonds, Empiric Student Property
15th Jun 2014 12:28
Whitbread looks like a reliable investment despite the imminent departure of Chairman Anthony Habgood, Matthew Goodman said in the Sunday Times's Inside the City column. The company was a mess when Habgood took over in 2005 but he has sold peripheral businesses to focus on Premier Inn and Costa Coff
Read more